EirGenix, Inc. (6589) Stock Price & Analysis
6589 Stock Chart & Stats
- Day’s Range
- TWD 42.80 - TWD 47.35
- 52-Week Range
- TWD 40.15 - TWD 84.30
- Previous Close
- TWD 46.80
- Volume
- N/A
- Average Volume (3M)
- 422.00K
- Market Cap
- TWD 14.12B
- Enterprise Value
- TWD 13.93B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- -0.72
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6589 FAQ
What was EirGenix, Inc.’s price range in the past 12 months?
What is EirGenix, Inc.’s market cap?
When is EirGenix, Inc.’s upcoming earnings report date?
How were EirGenix, Inc.’s earnings last quarter?
Is EirGenix, Inc. overvalued?
Does EirGenix, Inc. pay dividends?
What is EirGenix, Inc.’s EPS estimate?
How many shares outstanding does EirGenix, Inc. have?
What happened to EirGenix, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of EirGenix, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
EirGenix, Inc.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Li Cheng Liu
- Employees
- 1,000
- Website
- www.eirgenix.com
- Address
- TW
EirGenix, Inc. (6589) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

